Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2. / Drabe, Camilla Heldbjerg; Hansen, Ann Brit Eg; Rasmussen, Line Dahlerup; Larsen, Olav Ditlevsen; Møller, Axel; Mogensen, Trine H.; Helweg-Larsen, Jannik; Katzenstein, Terese L.

I: Infectious Diseases, Bind 53, Nr. 12, 2021, s. 953-958.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Drabe, CH, Hansen, ABE, Rasmussen, LD, Larsen, OD, Møller, A, Mogensen, TH, Helweg-Larsen, J & Katzenstein, TL 2021, 'Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2', Infectious Diseases, bind 53, nr. 12, s. 953-958. https://doi.org/10.1080/23744235.2021.1957144

APA

Drabe, C. H., Hansen, A. B. E., Rasmussen, L. D., Larsen, O. D., Møller, A., Mogensen, T. H., Helweg-Larsen, J., & Katzenstein, T. L. (2021). Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2. Infectious Diseases, 53(12), 953-958. https://doi.org/10.1080/23744235.2021.1957144

Vancouver

Drabe CH, Hansen ABE, Rasmussen LD, Larsen OD, Møller A, Mogensen TH o.a. Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2. Infectious Diseases. 2021;53(12):953-958. https://doi.org/10.1080/23744235.2021.1957144

Author

Drabe, Camilla Heldbjerg ; Hansen, Ann Brit Eg ; Rasmussen, Line Dahlerup ; Larsen, Olav Ditlevsen ; Møller, Axel ; Mogensen, Trine H. ; Helweg-Larsen, Jannik ; Katzenstein, Terese L. / Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2. I: Infectious Diseases. 2021 ; Bind 53, Nr. 12. s. 953-958.

Bibtex

@article{45608c6cd6e74e7388d26142a39149c4,
title = "Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2",
abstract = "Background: Manifestations and outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not well documented in patients with common variable immunodeficiency disorder (CVID). Methods: A Danish nationwide retrospective clinician-reported survey. Results: Eleven patients with CVID and SARS-CoV-2 infection were identified. The median age was 50 years (range 22–72). All were on immunoglobulin replacement therapy. Eight patients had other pre-existing co-morbidities. Three patients were asymptomatic during the SARS-CoV-2 infection while seven developed mild coronavirus disease 2019 (COVID-19). One patient had more severe disease with hypoxia and required oxygen therapy. This patient had multiple co-morbidities including well known risk factors for severe COVID-19. All patients recovered. Conclusions: The results suggest that CVID may not be a risk factor for severe COVID-19. However, further monitoring of this immunodeficient population is needed to confirm our observation.",
keywords = "common variable immunodeficiency, COVID-19, inborn errors of immunity, primary immunodeficiency, SARS-CoV-2",
author = "Drabe, {Camilla Heldbjerg} and Hansen, {Ann Brit Eg} and Rasmussen, {Line Dahlerup} and Larsen, {Olav Ditlevsen} and Axel M{\o}ller and Mogensen, {Trine H.} and Jannik Helweg-Larsen and Katzenstein, {Terese L.}",
note = "Funding Information: CD: financial grants for research: Takeda; AEH: financial grants for research and a teaching salary: CSL Behring; THM is funded by a grant from The Novo Nordisk Foundation (NNF21OC0067157); TLK: advisory board member or lecturer for Bristol-Myers Squibb, GlaxoSmithKline/ViiV, Jannsen, Merck Sharp & Dohme, Gilead Sciences, Chiesi, Vertex, CSLBehring, Shire and Takeda; research grant from Gilead Sciences; has participated in immunodeficiency conferences sponsored by CSLBehring, Shire and Takeda. LDR, ODL, AM, JHL: no competing interests. Publisher Copyright: {\textcopyright} 2021 Society for Scandinavian Journal of Infectious Diseases.",
year = "2021",
doi = "10.1080/23744235.2021.1957144",
language = "English",
volume = "53",
pages = "953--958",
journal = "Infectious Diseases",
issn = "2374-4235",
publisher = "Taylor & Francis",
number = "12",

}

RIS

TY - JOUR

T1 - Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2

AU - Drabe, Camilla Heldbjerg

AU - Hansen, Ann Brit Eg

AU - Rasmussen, Line Dahlerup

AU - Larsen, Olav Ditlevsen

AU - Møller, Axel

AU - Mogensen, Trine H.

AU - Helweg-Larsen, Jannik

AU - Katzenstein, Terese L.

N1 - Funding Information: CD: financial grants for research: Takeda; AEH: financial grants for research and a teaching salary: CSL Behring; THM is funded by a grant from The Novo Nordisk Foundation (NNF21OC0067157); TLK: advisory board member or lecturer for Bristol-Myers Squibb, GlaxoSmithKline/ViiV, Jannsen, Merck Sharp & Dohme, Gilead Sciences, Chiesi, Vertex, CSLBehring, Shire and Takeda; research grant from Gilead Sciences; has participated in immunodeficiency conferences sponsored by CSLBehring, Shire and Takeda. LDR, ODL, AM, JHL: no competing interests. Publisher Copyright: © 2021 Society for Scandinavian Journal of Infectious Diseases.

PY - 2021

Y1 - 2021

N2 - Background: Manifestations and outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not well documented in patients with common variable immunodeficiency disorder (CVID). Methods: A Danish nationwide retrospective clinician-reported survey. Results: Eleven patients with CVID and SARS-CoV-2 infection were identified. The median age was 50 years (range 22–72). All were on immunoglobulin replacement therapy. Eight patients had other pre-existing co-morbidities. Three patients were asymptomatic during the SARS-CoV-2 infection while seven developed mild coronavirus disease 2019 (COVID-19). One patient had more severe disease with hypoxia and required oxygen therapy. This patient had multiple co-morbidities including well known risk factors for severe COVID-19. All patients recovered. Conclusions: The results suggest that CVID may not be a risk factor for severe COVID-19. However, further monitoring of this immunodeficient population is needed to confirm our observation.

AB - Background: Manifestations and outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not well documented in patients with common variable immunodeficiency disorder (CVID). Methods: A Danish nationwide retrospective clinician-reported survey. Results: Eleven patients with CVID and SARS-CoV-2 infection were identified. The median age was 50 years (range 22–72). All were on immunoglobulin replacement therapy. Eight patients had other pre-existing co-morbidities. Three patients were asymptomatic during the SARS-CoV-2 infection while seven developed mild coronavirus disease 2019 (COVID-19). One patient had more severe disease with hypoxia and required oxygen therapy. This patient had multiple co-morbidities including well known risk factors for severe COVID-19. All patients recovered. Conclusions: The results suggest that CVID may not be a risk factor for severe COVID-19. However, further monitoring of this immunodeficient population is needed to confirm our observation.

KW - common variable immunodeficiency

KW - COVID-19

KW - inborn errors of immunity

KW - primary immunodeficiency

KW - SARS-CoV-2

U2 - 10.1080/23744235.2021.1957144

DO - 10.1080/23744235.2021.1957144

M3 - Journal article

C2 - 34375571

AN - SCOPUS:85112236286

VL - 53

SP - 953

EP - 958

JO - Infectious Diseases

JF - Infectious Diseases

SN - 2374-4235

IS - 12

ER -

ID: 302161956